Protocol ID93-008 
Page 11 
4. 12.5 Prior abdominal irradiation (small field or pelvic RT alone may be eligible). 
4. 12.6 Any contraindication to surgical re-exploration. 
4. 12.7 Patients with organ allografts. 
4.12.8 Patients who require or are likely to require cortiocosteroids for intercurrent 
disease. 
4.12.9 A history of another malignancy other than basal cell carcinoma, or 
squamous carcinoma of the skin, or less than 10 years elapsed since 
remission from other malignancies. 
4.12.10 Patients with any significant medical disease other than the malignancy. 
Patients with a major psychiatric illness are usually ineligible. Similarly, 
patients with unstable blood pressure, known CNS or seizure disorders, or 
severe diabetes mellitus will be ineligible. Patients with active infection are 
ineligible. 
4.12.11 Patients with known coronary artery disease, myocardial disease, or 
significant valvular heart disease. Patients with documented significant 
ventricular ectopy. Patients who are suspected of having any one of the 
above may be eligible, but only after thorough cardiac evaluation. 
5.0 RESEARCH 
PLAN 
5. 1 Registration 
All patients will be registered with the Patient Data Management System of M. D. 
Anderson Cancer Center (713) 792-6828 (Wanza Scott, R.N.). 
5.2 (a) Schema for labeling of TIL with neo*^ and treatment of ovarian cancer 
patients with intraperitoneal rIL-2 expanded purified CDS+CDS^ TIL and low dose 
rIL-2 (from Treatment Protocol ID92-015 (T92-0093). All patients who receive the 
retroi^al marked TIL must also be eligible and receive treatment under protocol 
ID92-015 (T92-0093). The treatment and evaluation of clinical response to the 
treatment is described in protocol ID92-015 on pp. 14-20. 
Expansion and Marking of CDS'*' TIL with neo ^ 
Treatment Protocol 
expansion In vitro labeling with GlNa ^ further expansion 
with rIL-2 ofTlL/TlL neo R 
In rlL-2 (ACCS 2) 
administration of 
(TIL + TIL neo R) 
plus rlL-2 to 
patients 
Recombinant DNA Research, Volume 19 
[469] 
